SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-058256
Filing Date
2023-11-02
Accepted
2023-11-02 16:23:34
Documents
65
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q algs-20230930.htm   iXBRL 10-Q 2919535
2 EX-31.1 algs-ex31_1.htm EX-31.1 18708
3 EX-31.2 algs-ex31_2.htm EX-31.2 18706
4 EX-32.1 algs-ex32_1.htm EX-32.1 10468
5 EX-32.2 algs-ex32_2.htm EX-32.2 10463
  Complete submission text file 0000950170-23-058256.txt   8594788

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT algs-20230930_def.xml EX-101.DEF 185383
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT algs-20230930.xsd EX-101.SCH 62152
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT algs-20230930_lab.xml EX-101.LAB 475240
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT algs-20230930_pre.xml EX-101.PRE 330937
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT algs-20230930_cal.xml EX-101.CAL 44488
59 EXTRACTED XBRL INSTANCE DOCUMENT algs-20230930_htm.xml XML 1328187
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 231372729
SIC: 2836 Biological Products, (No Diagnostic Substances)